Chief Oncology Clinical Development Leader

SJP Biotec GmbH; Zürich; Hybrid; CHF 260.000 - 420.000; Vollzeit

Zusammenfassung

SJP Biotec GmbH in Zürich is actively seeking a Chief Medical Officer to lead clinical development strategy for multiple indications and to act as the clinical face of the company. You will drive trial design, regulatory submissions, and biomarker-driven programs across global sites.

The ideal candidate has 10+ years in oncology clinical development with strong FDA/EMA interactions and a track record in breast cancer, NSCLC, or KRAS biology, complemented by publication/presentation excellence.

Qualifikationen

• MD with specialization in medical oncology and hematology.
• 10+ years in oncology clinical development with trial leadership.
• Proven IND/CTA submissions track record.
• Experience interacting with FDA and EMA.
• Biomarker-driven trial design expertise.
• Experience in breast cancer, NSCLC, and KRAS biology.
• Strong publication/congress presentation record.
• Excellent presentation and teamwork abilities.

Aufgaben

• Translate board directives and serve as the clinical face of the company.
• Lead clinical development across the SJP portfolio.
• Design Phase 2/3 protocols and oversee CTA/IND submissions.
• Develop biomarker-driven patient selection strategies.
• Build relationships with academic and clinical sites across regions.
• Lead regulatory strategy for accelerated pathways when applicable.

Kenntnisse

Clinical development leadership

IND/CTA submissions

Biomarker-driven trial design

Regulatory strategy

Stakeholder management

Team leadership

Scientific communication

Ausbildung

MD, oncology/hematology specialization

Jobbeschreibung

SJP Biotec GmbH in Zürich is actively seeking a Chief Medical Officer to lead clinical development strategy for multiple indications and to act as the clinical face of the company. You will drive trial design, regulatory submissions, and biomarker-driven programs across global sites.

The ideal candidate has 10+ years in oncology clinical development with strong FDA/EMA interactions and a track record in breast cancer, NSCLC, or KRAS biology, complemented by publication/presentation excellence.